Mitochondria-Related Nuclear Gene Expression in the Nucleus Accumbens and Blood Mitochondrial Copy Number After Developmental Fentanyl Exposure in Adolescent Male and Female C57BL/6 Mice

Cali A. Calarco, Megan E. Fox†, Saskia Van Terheyden, Makeda D. Turner, Jason B. Alipio, Ramesh Chandra and Mary Kay Lobo*

Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, United States

The potency of the synthetic opioid fentanyl and its increased clinical availability has led to the rapid escalation of use in the general population, increased recreational exposure, and subsequently opioid-related overdoses. The widespread use of fentanyl has, consequently, increased the incidence of in utero exposure to the drug, but the long-term effects of this type of developmental exposure are not yet understood. Opioid use has also been linked to reduced mitochondrial copy number in blood in clinical populations, but the link between this peripheral biomarker and genetic or functional changes in reward-related brain circuitry is still unclear. Additionally, mitochondrial-related gene expression in reward-related brain regions has not been examined in the context of fentanyl exposure, despite the growing literature demonstrating drugs of abuse impact mitochondrial function, which subsequently impacts neuronal signaling. The current study uses exposure to fentanyl via dam access to fentanyl drinking water during gestation and lactation as a model for developmental drug exposure. This perinatal drug-exposure is sufficient to impact mitochondrial copy number in circulating blood leukocytes, as well as mitochondrial-related gene expression in the nucleus accumbens (NAc), a reward-related brain structure, in a sex-dependent manner in adolescent offspring. Specific NAc gene expression is correlated with both blood mitochondrial copy number and with anxiety-related behaviors dependent on developmental exposure to fentanyl and sex. These data indicate that developmental fentanyl exposure impacts mitochondrial function in both the brain and body in ways that can impact neuronal signaling and may prime the brain for altered reward-related behavior in adolescence and later into adulthood.

Keywords: mitochondria, mitochondrial copy number, developmental drug exposure, fentanyl, nucleus accumbens, gene expression
INTRODUCTION

Opioid use in the United States has dramatically increased in recent years, with death by opioid overdose reaching epidemic proportions (1, 2). Despite the high potential for opioid misuse and abuse, they remain some of the most effective treatments for pain management available. More recently, the synthetic opioid fentanyl, which is 50–100× more potent than morphine, has become both commonly prescribed and commonly added to illicit drugs increasing both use in the general population and opioid-related overdose deaths (1, 2). The rise in both use and misuse of opioids seen in the general population has also been observed among pregnant women, increasing both in utero exposure to opioids and increasing the occurrence of neonatal opioid withdrawal syndrome (NOWS) (3–6). Previous work in both humans and rodents has shown that developmental exposure to traditional opioids like morphine and heroin can lead to behavioral and developmental differences into adolescence and adulthood, including altered attention, stress responsivity, and learning and memory (7–10). Recently, studies examining the impact of developmental exposure to fentanyl have revealed changes in behavior and somatosensory processing into adolescence and adulthood (11, 12).

In addition to the many neurobiological changes in reward related processing, and cycles of negative affect that are associated with opioid use, escalation of use, and substance use disorders (13–18), opioid exposure is also associated with high degrees of oxidative stress and oxidative damage both centrally and peripherally (19–23). Patients with opioid use disorders show higher levels of oxidative and inflammatory markers in blood serum (24), and are more likely to show markers of metabolic syndrome, indicative of increased risk for mortality due to heart disease or diabetes (25). Multiple pre-clinical studies have shown metabolic disruptions and oxidative damage in brain tissue after morphine or heroin exposure (19, 26). Oxidative damage in the form of increased reactive oxygen species and decreased antioxidant enzyme activity caused by drug use can lead to mitochondrial dysfunction and neurotoxicity as well as other cellular damage (22, 26). Mitochondria specifically both absorb inflammatory and metabolic damage (27–29) and mediate brain function, neuroplasticity, and early life brain development (30–34).

Mitochondrial dynamics and changes therein due to stress, damage or altered energy requirements impact mitochondrial copy number, the ratio of mitochondrial DNA to nuclear DNA, which can be used as a proxy for mitochondrial function (35, 36). While brain tissue is not readily available from patient populations and does not allow for repeated sampling over the course of development, mitochondrial copy number in blood leukocytes is readily accessible in both clinical and pre-clinical samples. Indeed, understanding how peripheral blood-derived mitochondrial DNA copy number is associated with gene expression and mitochondrial function in other tissues is an active and important avenue of investigation (36). With respect to opioid use, mitochondrial copy number is reduced and markers of mitochondrial damage are increased in both human heroin users and rats exposed to chronic morphine (37). In the rats, mitochondrial copy number was also reduced in brain tissue, specifically the hippocampus (37). In cell culture, acute fentanyl and methadone, but not morphine, specifically negatively impact mitochondrial morphology and function (38, 39). It is currently unclear how the changes in mitochondria, accumulating mitochondrial damage, and other behavioral effects of opioid use are related. While mitochondrial function in reward-related brain areas, such as NAc, does regulate anxiety-like behaviors in rodent models (40–42), work on how altered mitochondria function contributes to increases in psychiatric symptoms and mood disorders in individuals with opioid use disorders or opioid exposure (43–45) is still needed.

The relationship between opioid use and mitochondrial function is still actively being explored and the current study sought to determine if developmental exposure to fentanyl causes long-lasting changes in peripheral and central markers of mitochondrial dynamics comparable to those observed after adult opioid use. Further, we sought to understand how peripheral markers of mitochondrial dynamics relate to mitochondrial gene expression in the reward-related brain regions critical for mediating opioid use, escalation of use, and opioid use disorder, specifically the nucleus accumbens (NAc) (46–48). Neuronal morphology and signaling changes in NAc have been shown to be critical for regulating both reward and anxiety- and depression-like behaviors (49, 50). Finally, we examined how both blood mitochondrial copy number and NAc gene expression correlated with behavioral measures of anxiety-like behavior and body weight. In this study we expand on the previously developed model of perinatal fentanyl exposure (11, 12) to explore the effects on blood mitochondrial copy number and expression of mitochondrial-related genes in NAc in adolescent mice. In this pre-clinical model, the perinatal period of mouse development consisting of gestation through weaning roughly corresponds to the full gestational period in humans, due to the developmental differences between species (51, 52). To our knowledge, this is the first study to examine mitochondrial copy number or NAc gene expression after developmental fentanyl exposure and subsequent forced abstinence.

METHODS

Animals

All procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committees at the University of Maryland School of Medicine. Male and female C57BL/6J mice were bred to generate developmentally drug-exposed offspring in our facility. After verification of dam pregnancy by copulatory
plug, sires were removed, and water was replaced with fentanyl-containing water or vehicle (see below). Vehicle controls received plain tap water. Water was monitored daily for consumption and replenished as necessary until litters were weaned at P21. After weaning, offspring were housed two to five per cage in single-sex groups, in a temperature- and humidity-controlled vivarium. Food and water were available ad libitum, and lights were maintained on a 12-h cycle.

**Drugs**

At the time of pregnancy confirmation 10 µg/mL fentanyl citrate (Cayman Chemical; Cat# 22659) in tap water, or plain tap water (vehicle) was administered as the only source of available drinking water. This concentration has been reported previously for use in this developmental exposure model and was selected because mice will readily consume this dose, yet it does not cause motor deficits and is well-below LD50 of fentanyl in mice (11, 12). This dose has previously been shown to induce spontaneous withdrawal signs after weaning, but is not sufficient to disrupt maternal care behavior (11, 12).

**Behavior**

After weaning at P21, offspring were left undisturbed until beginning behavioral testing. Each animal underwent an elevated plus maze (EPM) test and splash test, with 24 h separating each test. Twenty-four hours after the final behavioral test on day P35 body weight was measured and tissues were collected. The tissues used for analysis here were obtained from a subset of mice whose developmental exposure to fentanyl and behavioral testing results have been previously published by Alipio et al. (11). Tissue analysis was conducted on all 12 of the male water and male fentanyl mice, while a subset of the female mice were used: 17/22 female water and 17/31 female fentanyl mice. These mice include offspring from 7 different dams receiving water and 10 dams receiving fentanyl. Average litter size was 6 pups for both groups (Mean, SEM - Water: 6.14, 0.553; Fentanyl: 6.4, 0.476). Mice were habituated to the testing room before all behavioral procedures.

To measure anxiety-like behavior, mice were placed in the center of the EPM and were allowed to roam freely for 5 min, as described previously (11, 53, 54). Time spent in the open and closed arms of the maze in addition to the number of times the mouse entered one of the open arms were measured using computer tracking software (TopScan CleverSys, Reston, VA). Open/Closed ratios were calculated by dividing the time spent in the open arms by the time spent in the closed arms.

The splash test was used to measure affective state as has been described previously (11, 54). Mice were placed in an empty glass cylinder and their dorsal coat surface was sprayed three times with a 10% sucrose solution. Five min video recordings were experimenter scored by a blinded experimenter for time spent grooming.

**Tissue Collection**

Twenty-four hours following the final behavioral assay, brains were removed, and trunk blood was collected. Blood was collected in a 1.5 mL microcentrifuge tube containing 10 µL EDTA (0.5 M, Invitrogen, Cat#15575) to reduce clotting, vortexed and stored at −80°C until further processing. Brains were place on ice, cut into 1 mm sections using a brain block (Braintree Scientific), and 14-gauge punches surrounding the anterior commissure, encompassing both NAc core and shell, were collected (2 per animal). Tissue punches were stored at −80°C until further processing.

**DNA Extraction and Analysis**

Trunk blood was thawed and homogenized to break up any clots. DNA was extracted from whole blood using a QiaAmp DNA Micro Kit (Qiagen, Germantown, MD; Cat# 56304) following manufacturer instructions. DNA quality and concentration were measured on a Nanodrop (Thermo Scientific), and DNA was diluted to 2 ng/µL for qPCR with PerfeCTa SYBR Green FastMix (Quantabio, Beverly, MA; Cat# 95072). To measure relative mitochondrial copy number, expression of the mitochondrial gene NADH dehydrogenase 1 (mit-Nd1) was compared to the nuclear gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh) using the 2−ΔΔCt method. Forward and reverse primer sets are as follows (F; R; 5′-3′): Gapdh AGGTGGTGTGAGACGGATTG, TGTAGACTGATGTTGAGGCTCA; mt-Nd1 TACAACATTTGCAGGC, TGTTAGTATGAGGCTGTC. Data was further normalized within sex, such that male animals exposed to fentanyl were compared to male controls and female animals that received fentanyl were compared to female controls.

**RNA Extraction and Analysis**

RNA was extracted from NAc tissue punches using Trizol (Invitrogen) and the MicroElute Total RNA Kit (Omega; Cat# R6831) with a DNase step (Qiagen, Germantown, MD; Cat# 79254). RNA quantity and concentration were measured on a Nanodrop (Thermo Scientific), and 400 ng of RNA was used to synthesize complementary DNA using a reverse transcriptase iScript complementary DNA synthesis kit (Bio-Rad, Hercules, CA; Cat# 1708891). Resulting cDNA was diluted to a concentration of 2 ng/µL, which was used to measure relative mRNA expression changes via quantitative PCR with PerfeCTa SYBR Green FastMix (Quantabio, Beverly, MA; Cat# 95072). Sixteen nuclear mitochondrial related genes were tested, and the primer sets are as follows (F; R; 5′-3′): CysC TACATGCT ACCAGGGCTCTC, TGAGGGCTATGCGCCCTATT; Drp1 GGGCACTTTAATTGGCCTCC, TGATTCTGGTGCGGTGGAAC; Egr3 CCGGTGACCAGTACGGATTT, TAATGGGCGTACCCAGTCGCT; Fis1 GGCTGCTTCCTCAAGTCAAAATC, GGAGAAGGGGAGGCGATG; Mfn1 TATCGATGCTTGGAGAT, GGCGATCAACAACACTTC; Mfn2 GGAGACCAACAGGGTGA, TGCACATGACTTTCCACGGC; Nrf1 AGACCTCTGGATTAGATTCC, CGTGGACTTTCACAACGACT; Nr1f AGACCTCTGGATTAGATTCC, CGTGGACTTTCACAACGACT; Ppar3 ACCTCATGATTGCTGTC, Opal1 CAGCTCAGAGACCCTGCCAA, TTCTCAACAGCAGCTGAGGT; Park2 GCACCTCA AGCAAGAATGC, TACAGATGCTGGGCCAAGG; Polε CGACATCTGTTGTCGTTTGGC; Tfb1m CAGCTCAGAGACCCTGCCAA, TTCTCAACAGCAGCTGAGGT; Tifam TATCGATGCTTGGAGAT, GGCGATCAACAACACTTC; Tjβ1m TACAGATGCTGGGCCAAGG; Tmtf ATCGTCTGGTTGTTTGGC; Tpl2a TACAGATGCTGGGCCAAGG; Tpr5f AACCAATACTGAC, TACAGATGCTGGGCCAAGG; Tsc22d1 TACAGATGCTGGGCCAAGG; Ubc9 TACAGATGCTGGGCCAAGG; Vps13b TACAGATGCTGGGCCAAGG; War1 TACAGATGCTGGGCCAAGG; Wnt8 TACAGATGCTGGGCCAAGG; Xbp1 TACAGATGCTGGGCCAAGG; Ykl40c TACAGATGCTGGGCCAAGG.
Calarco et al. Developmental Fentanyl Exposure and Mitochondria

FIGURE 1 | Mitochondrial copy number in blood and gene expression in NAc after developmental fentanyl exposure. (A) Developmental fentanyl decreases blood mitochondrial copy number in male, but not female adolescent mice. (B) Developmental fentanyl increases mRNA expression of Tfam in NAc in female, but not male mice. *p < 0.05.

CCCTTGATAGCCCA, TCCTTCGAAACTGAAACGCA; Tomm20 CTGTGCTCTGGGCACCTAAAC, AGGTTGCACACA GGTCTAAT.

All biological samples were run in duplicate, and samples were excluded from analysis if duplicates were not within one CT value. Further, some samples did not yield sufficient RNA to run all genes tested, therefore, these samples were not run for all 16 genes. Quantification of mRNA changes was performed using the $2^{-\Delta\Delta Ct}$ method, using Gapdh and respective male and female control groups to normalize expression as described above.

Statistics
All statistics were performed using GraphPad Prism version 9.1.2 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com). Behavioral data for the subset of mice used for tissue analysis were analyzed with two-way ANOVAs with Sidak post-hoc tests to compare within sex. Group data was analyzed for outliers using Grubb’s-test, and outliers were removed from further analysis (no more than one per group). Relative DNA and RNA concentrations were compared within sex with unpaired t-tests when assumptions of equal variance were met and a Welch’s corrected t-test when this assumption was violated. Data are presented as mean ± sem with individual data points overlaid. Simple linear regressions were used for correlations.

RESULTS
To determine if developmental fentanyl exposure is sufficient to modulate peripheral mitochondria, we measured mitochondrial copy number in blood collected from P35 adolescent mice that had been exposed to fentanyl from conception through weaning.

We did not observe an effect in female mice (Welch’s corrected $t = 0.677, df = 20.82, p > 0.05$), however, blood mitochondrial copy number was significantly reduced in male mice that had received perinatal fentanyl as compared to control male mice (Figure 1A: $t = 3.005, df = 24, p = 0.0061$).

Opioid exposure and withdrawal in adulthood can cause both oxidative stress as well as gene expression changes in multiple brain regions (22, 25, 37, 39). Opioids are also highly addictive drugs with high abuse potential, and as such, readily engage reward-related brain circuitry during drug exposure (48, 55–58). Therefore, we examined the expression of multiple genes related to mitochondrial function in the NAc to determine if the peripheral changes in mitochondria are related to central changes in mitochondrial-related pathways in a reward-related brain region. These data are summarized in Table 1.

We examined genes related broadly to multiple facets of mitochondrial function. Genes related to regulating the balance of mitochondrial fission and fusion to maintain mitochondrial number include the fission-related proteins dynamin-related protein 1 (Drp1) and mitochondrial fission 1 protein (Fis1), the fusion-related proteins mitofusin 1 and 2 (Mfn1, Mfn2), and OPA1 mitochondrial dynamin like GTPase (Opa1) (59). Gene expression for these fission and fusion-related proteins was not changed in NAc in either sex by developmental exposure to fentanyl. Genes involved in mitochondrial function, health, stress-resistance, mitophagy, and protein transport including cytochrome C (Cycs), parkin (Park2), PTEN induced kinase 1 (Pink1), and translocase of outer mitochondrial membrane 20 (Tomm20) (60) were also not changed in NAc in either sex after developmental fentanyl exposure.

Finally, we examined expression of genes related to transcription and transcriptional regulation of both nuclear
TABLE 1 | Relative gene expression of nuclear mitochondrial related genes in NAc.

| Gene                  | Sex  | Sex     | n  | Mean  | 95% CI     | Sex     | Sex     | n  | Mean  | 95% CI     | Analysis | p-value | Sig |
|-----------------------|------|---------|----|-------|------------|---------|---------|----|-------|------------|----------|---------|-----|
| **Fission- and fusion-related genes** |      |         |    |       |            |         |         |    |       |            |          |         |     |
| Drp1                  | Female | 1.00 | 10 | 0.6707–1.329 | 8 | 0.8643 | 0.7428–0.9858 | Welch's t-test | 0.3798 | n.s. |     |
|                       | Male  | 1.00 | 10 | 0.8393–1.161 | 8 | 0.8145 | 0.4416–1.187 | t-test | 0.2666 | n.s. |     |
| Fis1                  | Female | 1.00 | 12 | 0.820–1.180 | 11 | 1.067 | 0.8969–1.238 | t-test | 0.556 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9138–1.086 | 11 | 0.8957 | 0.7357–1.056 | t-test | 0.2157 | n.s. |     |
| Mfn1                  | Female | 1.00 | 12 | 0.823–1.168 | 12 | 1.032 | 0.8772–1.187 | t-test | 0.7603 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9288–1.07 | 11 | 0.9784 | 0.8127–1.14 | Welch's t-test | 0.7938 | n.s. |     |
| Mfn2                  | Female | 1.00 | 12 | 0.9157–1.084 | 12 | 1.021 | 0.9245–1.118 | t-test | 0.7197 | n.s. |     |
|                       | Male  | 1.00 | 12 | 0.9372–1.063 | 10 | 0.9929 | 0.8878–1.098 | t-test | 0.8943 | n.s. |     |
| Opa1                  | Female | 1.00 | 12 | 0.8864–1.114 | 9 | 1.022 | 0.9368–1.108 | t-test | 0.7443 | n.s. |     |
|                       | Male  | 1.00 | 12 | 0.9033–1.097 | 11 | 1.076 | 0.9393–1.213 | t-test | 0.3194 | n.s. |     |
| **Mitochondrial function, health, stress-resistance, mitophagy, and protein transport** |      |         |    |       |            |         |         |    |       |            |          |         |     |
| Cycs                  | Female | 1.00 | 9  | 0.7999–1.200 | 11 | 0.9385 | 0.7798–1.097 | t-test | 0.5868 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.8917–1.108 | 9  | 1.735 | 0.7091–2.760 | Welch's t-test | 0.1383 | n.s. |     |
| Park2                 | Female | 1.00 | 10 | 0.8322–1.168 | 12 | 1.061 | 0.9342–1.189 | t-test | 0.5148 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9005–1.099 | 9  | 1.01 | 0.8131–1.207 | t-test | 0.916 | n.s. |     |
| Pink1                 | Female | 1.00 | 10 | 0.7716–1.228 | 12 | 0.7191 | 0.8210–1.287 | t-test | 0.7191 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.8355–1.164 | 9  | 0.8873 | 0.6134–1.161 | t-test | 0.4136 | n.s. |     |
| Tomm20                | Female | 1.00 | 10 | 0.8274–1.173 | 12 | 1.159 | 1.012–1.307 | t-test | 0.1313 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.8941–1.106 | 9  | 0.925 | 0.6860–1.164 | Welch's t-test | 0.524 | n.s. |     |
| **Nuclear transcription factors and transcriptional co-activators** |      |         |    |       |            |         |         |    |       |            |          |         |     |
| Egr3                  | Female | 1.00 | 12 | 0.7853–1.215 | 12 | 0.9545 | 0.8528–1.056 | Welch's t-test | 0.6794 | n.s. |     |
|                       | Male  | 1.00 | 12 | 0.8669–1.133 | 11 | 1.125 | 0.8940–1.356 | t-test | 0.2994 | n.s. |     |
| Nrf1                  | Female | 1.00 | 11 | 0.8882–1.112 | 12 | 1.125 | 0.8940–1.356 | t-test | 0.2969 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9055–1.095 | 11 | 1.043 | 0.7722–1.115 | t-test | 0.5289 | n.s. |     |
| Nrf2                  | Female | 1.00 | 12 | 0.7022–1.298 | 12 | 0.9898 | 0.7989–1.181 | t-test | 0.9502 | n.s. |     |
|                       | Male  | 1.00 | 10 | 0.8929–1.107 | 9  | 1.234 | 0.4896–1.978 | Welch's t-test | 0.4934 | n.s. |     |
| Pgc1α                 | Female | 1.00 | 12 | 0.7647–1.235 | 10 | 0.9395 | 0.7330–1.146 | t-test | 0.6785 | n.s. |     |
|                       | Male  | 1.00 | 10 | 0.8878–1.112 | 8  | 0.8442 | 0.4007–1.288 | Welch's t-test | 0.4451 | n.s. |     |
| **Mitochondrial transcriptase and transcription factors** |      |         |    |       |            |         |         |    |       |            |          |         |     |
| Polγ                  | Female | 1.00 | 9  | 0.9216–1.078 | 10 | 1.059 | 0.8985–1.219 | Welch's t-test | 0.4693 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9416–1.058 | 7  | 0.99 | 0.5802–1.400 | Welch's t-test | 0.9549 | n.s. |     |
| Tiam                  | Female | 1.00 | 12 | 0.8794–1.121 | 10 | 1.183 | 1.043–1.322 | t-test | 0.0381 | * |     |
|                       | Male  | 1.00 | 11 | 0.8720–1.128 | 10 | 0.8953 | 0.7612–1.030 | t-test | 0.2207 | n.s. |     |
| Tfb1m                 | Female | 1.00 | 10 | 0.8849–1.151 | 9  | 0.946 | 0.8401–1.052 | t-test | 0.5231 | n.s. |     |
|                       | Male  | 1.00 | 11 | 0.9189–1.081 | 6  | 1.142 | 0.6122–1.672 | Welch's t-test | 0.5254 | n.s. |     |

Significant results in bold.

*p < 0.05, n.s. = not significant.

and mitochondrial genome genes, broad regulators of overall patterns of gene expression (61, 62). Transcription factors and transcriptional co-activators that regulate nuclear genes related to mitochondrial function including Early Growth Response 3 (Egr3), nuclear respiratory factor 1 (Nrf1), nuclear factor, erythroid 2 like 2 (Nrf2), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α) were not changed in NAc in either sex after developmental fentanyl exposure. DNA Polymerase Subunit Gamma-1 (Polγ), a mitochondrial DNA polymerase which conducts mitochondrial DNA replication was not altered by developmental fentanyl, however, the mitochondrial transcription factor transcription factor A (Tiam) increased expression in female mice that had been developmentally exposed to fentanyl (Figure 1B). Tiam expression was not changed in male mice, nor were changes observed in either sex of transcription factor B1, mitochondrial (Tfb1). Notably, the change in expression of Tiam is double dissociated from the mitochondrial copy number finding in male mice.

While many of the genes examined did not show statistically significant differences, we noticed high degrees of variability in gene expression for many genes, therefore, we decided to explore if this variability in gene expression was related either to peripheral mitochondrial copy number, performance in the
measured behavioral tests, or other factors that may relate to overall metabolic function, specifically body weight at the time of sacrifice. The behavioral data used here represents a subset of the previously published animals (11) used for the molecular analysis. In this subset of animals, male animals showed increased anxiety-like behavior in the EPM, indicated by a reduced ratio of time spent in the open arms of the maze over the time spent in the closed arms, but there was no effect in females (mean ratio, SEM - male control: 0.4081, 0.07036; male fentanyl: 0.1919, 0.02859; female control: 0.3661, 0.0441; female fentanyl: 0.3318, 0.0401) [main effect of drug $F_{(1,54)} = 7.419, p = 0.0087$; post-hoc male adjusted $p = 0.0082$, female adjusted $p > 0.05$]. There was a main effect of sex in the splash test, with females spending more time grooming $[F_{(1,54)} = 10.48, p = 0.0021]$, however there was no effect of fentanyl or interaction (mean seconds, SEM - male control: 99.01, 5.497; male fentanyl: 81.83, 11.30; female control: 117.2, 4.954; female fentanyl: 112.8, 8.543). Finally, while males weighed more than females $[F_{(1,54)} = 5.622, p = 0.0213]$, we did not observe an effect of fentanyl on weight at this time point in this cohort (mean grams, SEM - male control: 18.21, 0.6542; male fentanyl: 18.82, 0.4767; female control: 17.2, 0.6829; female fentanyl: 17.11, 0.4271). We performed Pearson correlations on our copy number, gene expression and behavioral data and all correlations are described in Supplementary Table 1. Blood mitochondrial copy number showed a significant positive correlation with NAc Drp1, Mfn2, and Nrf2 in female control mice (Figure 2) but shows no relationship with NAc gene expression in female mice exposed to fentanyl or male mice of either condition. Specifically, there was no correlation between blood copy number with NAc Tfam expression in female mice, which was significantly increased in fentanyl-exposed mice. While developmental fentanyl does not change blood mitochondrial copy number in female adolescent mice, it does seem to disrupt the correlations with NAc gene expression seen in control mice, possibly indicating an uncoupling of peripheral and central mitochondrial function potentially unique to female mice, or a more complex relationship between NAc gene expression and blood mitochondria copy number in the context of developmental drug exposure.

Conversely, the ratio of time spent in the open/closed arms of the elevated plus maze, an indicator of anxiety-like behavior, showed no correlation with gene expression in control animals, but is correlated with a number of genes in animals that had been exposed to fentanyl (Figure 3). In female mice EPM open/closed ratio negatively correlates with both Drp1 and Pgc1α expression in NAc (Figure 3A). In male animals, EPM open/closed ratio positively correlates with NAc expression of Fis1, Park2, and Tomm20 (Figure 3B). Time spent grooming in the splash test did not correlate with NAc gene expression for either sex under either drug exposure condition. Body weight positively correlated with NAc Tfb1 expression in male control mice, and negatively with Tfb1 in female mice exposed to fentanyl (Figure 3C). In male mice exposed to fentanyl body weight was negatively correlated with NAc expression of Pnk1 (Figure 3D).

**DISCUSSION**

Opioid exposure is related to increased oxidative damage and mitochondrial damage in adulthood, and many negative impacts of chronic opioid use can be particularly long-lasting if the drug is encountered during development, leading to altered behavior and neurological function (9, 20, 24, 63). Opioid use and opioid use disorders are also associated with an increase in psychiatric mood symptoms as well as mood and anxiety disorders (43, 44). The current study examined how developmental exposure to the synthetic opioid fentanyl altered blood mitochondrial copy number, mitochondrial gene expression, and how these measures related to each other and anxiety-like behaviors in adolescent male and female mice. We showed that developmental exposure to fentanyl reduces blood mitochondrial copy number in male mice and increases NAc expression of Tfb1 mRNA in female mice. Additionally, mice exposed to fentanyl showed different patterns of correlation between blood mitochondrial copy number, anxiety-like behavior, weight, and NAc gene expression in a sex-dependent manner.

Mitochondria are particularly impacted by oxidative stress both as producers and scavengers of reactive oxygen species, and
in turn are a critical mediator in downstream cellular processing and homeostatic changes in response to such oxidative stress. Mitochondrial DNA is particularly susceptible to oxidative damage compared to nuclear DNA, as it both lacks protective histone proteins and mitochondria have less robust DNA-repair machinery than nuclei (64). The mitochondrial genome is maintained in a highly dynamic equilibrium, existing in multiple copies per cell, with 1–10 copies per mitochondrion.
and multiple mitochondria per cell, depending on cell type (35, 65). Because the mitochondrial genome codes for most of the enzymatic subunits needed for oxidative phosphorylation, mitochondrial copy number can be used as an indicator of mitochondrial biogenesis (35, 66), and changes in mitochondrial copy number may contribute to oxidative stress, inflammation, and mitochondrial dysfunction (67, 68).

Mitochondrial dysfunction has been linked to disorders from diabetes, to cancer, and more recently to stress, psychiatric illnesses and substance use disorders (28, 69–74). Mitochondria copy number is increased in patients with bipolar disorder (75, 76), early childhood maltreatment or adversity (77), and increased in the prefrontal cortex and hippocampus of rats that had undergone cocaine self-administration, but is decreased in human heroin users and mice and rats exposed to chronic heroin (37). Our findings here mimic the decrease in copy number seen in male rodents, despite the developmental exposure and abstinence at the time of tissue collection used here. In the human patients, copy number did partially recover 3 months after initiation of heroin abstinence, although even after 6 months copy number had not fully recover to control levels (37). The clinical population represented female patients, although we did not observe changes in copy number in female mice. Further work will be needed to determine if opioids impact mitochondrial copy number comparably in men and women. Sex differences in substance use, substance use disorders, and successful abstinence have been readily observed for multiple used drugs, including opioids (78–82). A unique feature of the current study is the consistency of gestational fentanyl exposure in utero as our sample represents multiple litters consisting of both males and females. Fentanyl dose during the post-natal period was dependent on individual variance in pup milk or water consumption until weaning.

Although a growing number of studies are examining peripheral copy number, fewer studies are relating this measure to changes in other tissues, including the brain. In neurons, mitochondrial quality control and proper functioning impacts many aspects of cellular function related to signaling and circuit function (31). Specifically, in addition to providing the high levels of ATP necessary to maintain electro-chemical gradients, mitochondria buffer both intracellular calcium and reactive oxygen species, influence apoptosis, and have been shown to be critical for dendritic spine formation (31–33). Further, mitochondria and mitochondrial related genes in the NAc specifically have been shown to mediate behavioral responding for cocaine in a mouse model of substance use disorder (34, 83, 84), indicating mitochondrial function in NAc as a specific node for influencing the response to addictive drugs. Of the genes examined in NAc here, only Tfm showed increased expression. Interestingly, Tfm, because it binds to the mitochondrial DNA as a transcription factor, also has been shown to protect mitochondrial DNA from damage due to oxidative stress (61, 85, 86). Thus, it is possible there may be oxidative damage in NAc caused by developmental fentanyl exposure, and the increased expression of Tfm may be neuroprotective in female mice, consistent with their unchanged blood copy number. The sex-specific nature of this effect, and the lack of changes in other genes of interest may indicate tight regulation of mitochondrial function in NAc through development and during adolescence despite the drug exposure. Future studies should examine more direct measures of mitochondria in NAc, such as copy number. Heroin can reduce mitochondrial copy number in hippocampus indicating drug exposure can influence copy number in brain (37), but copy number can vary independently with brain region, and changes in one area may not predict changes in other connected brain regions (87). Importantly, differences in oxidative damage or gene expression may vary even within the NAc itself, as the NAc core, medial shell, and lateral shell all have previously described variance in regulating reward-related behaviors (88–92). The tissue used in this study included all subregions of the NAc, and future work will be needed to further dissect any unique subregion responses to developmental fentanyl. Mitochondrial morphology in NAc, regulated by many of the genes examined here, is also responsive to both drug exposure (34) and trait-anxiety measures possibly established during development (40). Fentanyl does impact mitochondrial morphology in neuronal-like NG108–15 cells (39), but this has not been demonstrated in any neuronal type in vivo. Further, the impact of developmental fentanyl exposure on mitochondria may be cell-type selective; beyond neurons, astrocyte function is altered by opioid exposure (93–95) and it is possible that changes in these glial cells or the immune-related microglia mimic changes seen in peripheral immune cells.

Our data indicate that blood mitochondrial copy number does vary systematically with NAc mitochondrial-related nuclear genes, specifically Drp1, Mfn1, and Nrf1, with higher copy number corresponding to higher gene expression. Drp1 regulates mitochondrial fission, promoting the formation of more mitochondria. In the brain, Drp1 is involved in new dendritic spine formation (33). While opioid exposure is linked to a decrease in dendritic spines, due to internalization of mu opioid receptors (96, 97), the correlation described here is in female mice specifically, which were resistant to both changes in blood copy and changes in EPM anxiety-like behavior, although fentanyl did disrupt the correlation with NAc gene expression. Mfn2 is usually considered a fusion-related protein (98), but it also plays critical role in mediating mitochondrial contact points with the endoplasmic reticulum independent of fusion and its expression in NAc has been linked to anxiety-like behaviors (40), Nrf1, as a nuclear transcription factor, regulates expression of other mitochondrial related genes including those related to mitochondrial respiratory function as well as genes involved in RNA metabolism, DNA damage repair, and ubiquitin-mediated protein degradation (99). While the role of mitochondrial related gene expression and function in NAc with respect to drug exposure is still a relatively new area of investigation, mitochondrial function within reward circuits has already been linked repeatedly to anxiety-like behaviors (41). Specifically, expression of mitochondrial related genes, mitochondria complex I and II function, and mitochondrial respiratory capacity impact both trait anxiety and expressions social dominance (40, 100, 101). Further, increases in ventral tegmental area dopamine input to NAc or D1-dopamine receptor agonism in NAc can increase both mitochondrial respiratory
activity and facilitate social dominance expression in previously identified higher-anxiety rats (102). Both NRF1 and NRF2 regulate mitochondrial function in reward-related brain regions (103, 104), and global NRF2 knockdown is sufficient to decrease open arm time in rats in an EPM (104). NRF1 knockdown did not impact EPM behavior, but did alter expression of other mitochondrial-related proteins in the amygdala, hippocampus and prefrontal cortex (103). Since affect, mood, and anxiety are all impacted by drug use (57, 105–107), including opioid use (43, 44) and withdrawal (108), altered mitochondrial function may be a common underlying mechanism for trait anxiety or altered anxiety-like behavior after exposure to opioids and other drugs. Future work on both the genes of interest identified here and other mitochondrial processes is needed to fully understand their role in regulating behavior after drug exposure.

While these relationships with NAc gene expression exist in control animals, developmental fentanyl presented other relationships with gene expression, which negatively correlated with EPM behavior in female mice and positively in male mice. Both Drp1 and Pgc1a, the genes correlated in female mice, have both been shown in NAc to mediate enhanced behavioral responding to cocaine (34, 83), and here higher expression is related to less time spent in the open arms of the EPM. Conversely, Fis1, Park2, and Tomm20 all have functions in mitochondrial degradation pathways (109–112), potentially indicating higher degrees of mitochondrial damage or turn over in male mice after fentanyl which also have reduced blood copy number and significantly reduced open arm time in the EPM (11). Fentanyl also produced negative correlations between body weight and NAc expression of Pnk1 in male mice and with Tfb1 in female mice. Pink1 is protective against mitochondrial dysfunction (113), and as a mitochondrial transcription factor Tfb1 might have the same protective effects for mitochondrial DNA as Tfam. Future studies will be needed to further understand the relationship between weight, NAc gene expression, and opioid exposure. While some genes did correlate with behavior, Tfam did not, indicating that developmental fentanyl causes dissociable changes in the periphery and in NAc, and each of these tissues independently relate to behavior. Further, the sex differences seen here in both EPM behavior and in gene expression correlations are consistent with previous work showing important sex differences in NAc gene expression in the context of resilience to stress (114) and sex differences in the NAc proteome after exposure to nicotine, a commonly used drug (115).

It is important to note that in this study it is impossible to distinguish if the changes and relationships described here are due to the fentanyl exposure itself or due to the experience of going through withdrawal from the fentanyl after weaning. This regimen of fentanyl exposure is sufficient to induce spontaneous withdrawal signs (12), and it is unclear if the changes in behavior during adolescence are a prolonged result of withdrawal-related plasticity (58), or indicative of shifted baselines in stress reactivity caused by developmental insult (6, 9, 10). It is also possible, that the developmental timing of withdrawal (at weaning rather than at birth) may be significant. As mitochondria in the brain and body have been previously shown to modulate responses to both acute psychological stress (27), and mediate some of the developmental impacts on the brain of early-life stress (30), it is possible the effects seen here represent the mitochondrial response to opioid withdrawal (116–118). Future studies involving both continuous access to fentanyl and longer periods of abstinence into adulthood will be necessary to resolve this distinction and determine the persistence of these effects.

Taken together, these data indicate developmental fentanyl exposure has similar effects on offspring mitochondrial copy number as adult opioid use potentially including oxidative damage that disturbs mitochondrial function. Changes in the NAc are only one component of the reward circuits that may be impacted by this developmental opioid exposure and future work should examine the impacts on other brain regions, which may show stronger more significant relationships with blood mitochondrial copy number or behavior than those demonstrated here. The relationships with brain gene expression and behavior indicate coordinated responding throughout the body to the developmental insult of fentanyl exposure and future studies should further explore this relationship to better predict health and supplement treatment for infants with prenatal opioid exposure.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Institutional Animal Care and Use Committee at the University of Maryland School of Medicine.

**AUTHOR CONTRIBUTIONS**

ML, RC, CC, and MF were responsible for study concept and design. JA and MF designed the perinatal exposure paradigm. MF, JA, and MT managed breeding, fentanyl dosing, and behavioral testing. MF, JA, SVT, and CC collected tissues and performed experiments. CC performed data analysis. CC and ML drafted the manuscript. MF provided critical revision of the manuscript for content. All authors critically reviewed content and approved the final version for publication.

**FUNDING**

This work was funded by NIH R01DA038613, NIH R01MH106500, T32DK098107, F32DA052966, and K99DA050575.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.737389/full#supplementary-material
REFERENCES

1. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States 2013. Med Care. (2016) 54:901–6. doi: 10.1097/MLR.0000000000000625

2. Ryan SA. Calculating the real costs of the opioid crisis. Pediatrics. (2018) 141:18–21. doi: 10.1542/peds.2017-4129

3. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. Morb Mortal Wkly Rep. (2018) 67:845–9. doi: 10.15585/mmwr.mm6731a1

4. Badiani A, Blein D, Epstein D, Calu D, Shaham Y. Opiate versus psychostimulant addiction: a novel approach for biomarker discovery and biochemical understanding of the disorder. Br J Pharmacol. (2020) 12:003 doi: 10.1101/gr.269381.120

5. Clay Montier LL, Deng JJ, Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. J Neuroendocrinol. (2020) 32:13–33. doi: 10.1111/jne.12786

6. Alipio JB, Brockett AT, Fox ME, Tennyson SS, DeBettencourt CA, El-Metwally D, et al. Enduring consequences of perinatal fentanyl exposure in mice. Addict Biol. (2021) 26:e12895. doi: 10.1111/adb.12895

7. Honein MA, Boyle C, Redfield RR. Public health surveillance of prenatal opioid exposure in mothers and infants. Pediatrics. (2019) 143:e20183801. doi: 10.1542/peds.2018-3801

8. Whitman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy. (2014). 2014:906723. doi: 10.1155/2014/906723

9. Dhar SN, Shanker S, Ghosal S, Graber MR, Koppula B, Sethi S, et al. Mitofusin-2 in the nucleus accumbens regulates anxiety and depression-like behaviors through mitochondrial and neuronal actions. Biol Psychiatry. (2021) 89:1033–44. doi: 10.1016/j.biopsych.2020.12.003
81. Lee CWS, Ho IK. Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors. Mol Pain. (2013) 9:1–10. doi: 10.1186/1744-8609-9-45

82. Becker JB, Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neuroperopharmacology. (2019) 44:166–83. doi: 10.1038/s41386-018-0123-6

83. Chandra R, Engelm F, Francis TC, Konakl Patt M, Patel D, Lobo MK, et al. Role for pexisoxin prokaryotic-activated receptor gamma coactivator-1α in nucleus accumbens neuron subtypes in cocaine action. Biol Psychiatry. (2017) 81:564–72. doi: 10.1016/j.biopsych.2016.10.024

84. Cole S, Chandra R, Harris M, Patel I, Wang T, Kim H, et al. Cocaine-induced neuron subtype mitochondrial dynamics through Egr3 transcriptional regulation. Mol Brain. (2021) 14:101. doi: 10.1186/s13041-021-00800-y

85. Xu S, Zhong M, Zhang L, Wang Y, Zhou Z, Hao Y, et al. Overexpression of Tfam protects mitochondria against β-amyloid-induced oxidative damage in SH-SY5Y cells. FEBS J. (2009) 276:3800–9. doi: 10.1111/j.1742-4658.2009.07094.x

86. Feng Q, Shao M, Han J, Tang T, Zhang Y, Liu F, et al. A potential α-subunit of mitochondrial phospholipid scramblase 2 in mouse brain. Biochim Biophys Acta - Bioenerg. (2011) 1807:270–4. doi: 10.1016/j.bjbioad.2010.11.016

87. Laurent V, Leung B, Maidment N, Balleine BW. μ- and δ-Opioid-receptor processes in the accumbens core and shell differentially mediate the influence of reward-guided and stimulus-guided decisions on choice. J Neurosci. (2012) 32:1875–83. doi: 10.1523/JNEUROSCI.4688-11.2012

88. Paciotta S, Berridge KC. Dopamine or opioid stimulation of nucleus accumbens similarly amplify cue-triggered “wanting” for reward: entire core and medial shell mapped as substrates for PIT enhancement. Eur J Neurosci. (2013) 37:1529–40. doi: 10.1111/ejn.12174

89. Di Ciano P, Robbins TW, Everitt BJ. Differential effects of individual opioids on the morphology of spines depend upon the critical modulators of drug use and abuse. Neuropsychopharmacology. (2015) 55:492–9. doi: 10.1038/jn.2013.014-0370-a

90. Khalifeh S, Oryan S, Digahle H, Shaezadfe Z, Maghsoudi N, et al. Complexity of compensatory effects in Nfr1 knockdown: linking undeveloped anxiety-like behavior to prevented mitochondrial dysfunction and oxidative stress. Cell Mol Neurobiol. (2016) 36:553–63. doi: 10.1007/s10571-015-0236-0

91. Khalifeh S, Oryan S, Digahle H, Shaezadfe Z, Khodagholi F, Maghsoudi N, et al. Involvement of Nrf2 in development of anxiety-like behavior by linking Bcl2 to oxidative phosphorylation: estimation in rat hippocampus, amygdala, and prefrontal cortex. J Mol Neurosci. (2015) 55:492–9. doi: 10.1007/s10571-014-0370-a

92. Adebayo M, Singh S, Singh AP, Dasgupps S. Mitochondrial fusion and fission: the fine-tune balance for cellular homeostasis. FASEB J. (2021) 35:1–13. doi: 10.1096/fj.202100067R

93. Satoh JI, Kawan N, Yamamoto Y. Pathway analysis of ChIP-seq-based NRR1 target genes suggests a logical hypothesis of their involvement in the pathogenesis of neurodegenerative diseases. Gene Regul Syst Biol. (2013) 2013:139–52. doi: 10.4137/GRSBJ.S13204

94. Beyer F, Garcia-Garcia I, Heinrich M, Schroeter ML, Sacher J, Luck T, et al. Neuroanatomical correlates of food addiction symptoms and body mass index in the general population. Hum Brain Mapp. (2019) 40:2747–58. doi: 10.1002/hbm.24557

95. Khalifeh S, Oryan S, Digahle H, Shaezadfe Z, Khodagholi F, Maghsoudi N, et al. Complexity of compensatory effects in Nfr1 knockdown: linking undeveloped anxiety-like behavior to prevented mitochondrial dysfunction and oxidative stress. Cell Mol Neurobiol. (2016) 36:553–63. doi: 10.1007/s10571-015-0236-0

96. Kaufling J, Aston-Jones G. Persistent adaptations in afferents to the lateral hypothalamus. Front Mol Neurosci. (2015) 5:0003. doi: 10.3389/fnmol.2015.00003

97. Lüthi A, Lüscher C. Pathological circuit function underlying addiction and anxiety disorders. Nat Neurosci. (2014) 17:1635–43. doi: 10.1038/nmn.3849

98. Hutn MG, Parikh V, Gould TJ. Nicotine addiction and psychiatric disorders. De Biasi M, editor. Nicotine Use in Mental Illness and Neurological Disorders. Amsterdam: Elsevier Inc. (2015). p. 199–208.

99. Khalifeh S, Oryan S, Digahle H, Shaezadfe Z, Khodagholi F, Maghsoudi N, et al. Involvement of Nrf2 in development of anxiety-like behavior by linking Bcl2 to oxidative phosphorylation: estimation in rat hippocampus, amygdala, and prefrontal cortex. J Mol Neurosci. (2015) 55:492–9. doi: 10.1007/s10571-014-0370-a

100. Taussig LF, Erazo-Flores CE, Beaudoin C, Deutschman AB, et al. Complexity of compensatory effects in Nfr1 knockdown: linking undeveloped anxiety-like behavior to prevented mitochondrial dysfunction and oxidative stress. Cell Mol Neurobiol. (2015) 35:16362–76. doi: 10.1002/hbm.2457064. doi: 10.3389/fnmol.2021.657064

101. Chartoff EH, Carlezon WAJ. Drug withdrawal conceptualized as a stressor. Behav Pharmacol. (2014) 25:473–92. doi: 10.1097/FBP.0000000000000808

102. Neugebauer NM, Einstein EB, Lopez MB, McClure-Begley TD, Mineur YS, Picciotto MR. Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacol Biochem Behav. (2013) 109:77–83. doi: 10.1016/j.pbb.2013.04.015

103. Kaufling J, Aston-Jones G. Persistent adaptations in afferents to ventral tegmental dopamine neurons after opiate withdrawal. Front Mol Neurosci. (2015) 5:0003. doi: 10.3389/fnmol.2015.00003

Frontiers in Psychiatry | www.frontiersin.org
November 2021 | Volume 12 | Article 737389
12
